|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001554,
umls-concept:C0003873,
umls-concept:C0030705,
umls-concept:C0031327,
umls-concept:C0036043,
umls-concept:C0205210,
umls-concept:C0442117,
umls-concept:C0443315,
umls-concept:C0524527,
umls-concept:C0666743,
umls-concept:C0871261,
umls-concept:C0920321,
umls-concept:C1517004,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2006-5-2
|
|
pubmed:abstractText |
To assess safety, clinical response, and pharmacokinetics of subcutaneous (SC) and intramuscular (IM) doses of an experimental formulation of infliximab [including experimental SC doses following administration of commercially-formulated intravenous (IV) infliximab] in patients with rheumatoid arthritis (RA) refractory to methotrexate.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0315-162X
|
|
pubmed:author |
pubmed-author:Bouman-ThioEstherE,
pubmed-author:DurezPatrickP,
pubmed-author:EverittDaniel EDE,
pubmed-author:GrahamMartin AMA,
pubmed-author:HoussiauFrédéricF,
pubmed-author:JolyJohanJ,
pubmed-author:MascelliMary AnnMA,
pubmed-author:SiscoDeborahD,
pubmed-author:Van HartingsveldtBartB,
pubmed-author:WesthovensRenéR,
pubmed-author:ZhuYaoweiY
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
33
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
847-53
|
|
pubmed:meshHeading |
pubmed-meshheading:16583466-Adult,
pubmed-meshheading:16583466-Aged,
pubmed-meshheading:16583466-Antibodies, Monoclonal,
pubmed-meshheading:16583466-Antibody Formation,
pubmed-meshheading:16583466-Antirheumatic Agents,
pubmed-meshheading:16583466-Arthritis, Rheumatoid,
pubmed-meshheading:16583466-Dose-Response Relationship, Drug,
pubmed-meshheading:16583466-Drug Administration Schedule,
pubmed-meshheading:16583466-Drug Resistance,
pubmed-meshheading:16583466-Female,
pubmed-meshheading:16583466-Humans,
pubmed-meshheading:16583466-Injections, Intramuscular,
pubmed-meshheading:16583466-Injections, Subcutaneous,
pubmed-meshheading:16583466-Male,
pubmed-meshheading:16583466-Methotrexate,
pubmed-meshheading:16583466-Middle Aged,
pubmed-meshheading:16583466-Pilot Projects
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Clinical Trial, Phase I
|
